See more : Skillz Inc. (SKLZ) Income Statement Analysis – Financial Results
Complete financial analysis of Seres Therapeutics, Inc. (MCRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seres Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- M M Forgings Limited (MMFL.NS) Income Statement Analysis – Financial Results
- CAR Group Limited (CAR.AX) Income Statement Analysis – Financial Results
- SPC Nickel Corp. (SPCNF) Income Statement Analysis – Financial Results
- Colfax Corporation (CFX) Income Statement Analysis – Financial Results
- Public Bank Berhad (PBLOF) Income Statement Analysis – Financial Results
Seres Therapeutics, Inc. (MCRB)
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 126.33M | 7.13M | 144.93M | 33.22M | 34.51M | 28.27M | 32.10M | 21.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 704.00K | 1.00M | 1.73M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 728.00K | 10.72M | 0.00 | 0.00 |
| Gross Profit | 125.62M | 6.12M | 143.20M | -57.36M | -45.64M | -67.69M | -57.36M | -60.22M | -728.00K | -10.72M | 0.00 | 0.00 |
| Gross Profit Ratio | 99.44% | 85.91% | 98.80% | -172.68% | -132.26% | -239.46% | -178.68% | -276.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.86M | 172.92M | 141.89M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 38.10M | 10.72M | 4.81M | 2.08M |
| General & Administrative | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Other Expenses | 0.00 | 1.00M | -1.73M | 981.00K | 1.07M | 170.00K | 425.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 233.60M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Cost & Expenses | 234.31M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Interest Income | 7.30M | 3.06M | 2.87M | 946.00K | 1.03M | 0.00 | 0.00 | 2.23M | 638.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.18M | 6.02M | 2.91M | 2.92M | 502.00K | 1.17M | 1.59M | 969.00K | 555.00K | 0.00 | 42.00K | 0.00 |
| Depreciation & Amortization | 6.24M | 11.85M | 9.22M | 8.89M | 9.83M | 7.86M | 7.26M | 4.21M | 728.00K | 190.00K | 88.00K | 25.00K |
| EBITDA | -94.31M | -237.51M | -56.72M | -77.31M | -59.95M | -91.08M | -82.12M | -88.63M | -54.13M | -14.89M | -5.96M | -3.01M |
| EBITDA Ratio | -74.65% | -3,425.04% | -43.24% | -259.53% | -197.90% | -354.77% | -262.11% | -396.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.98M | -246.49M | -64.49M | -88.13M | -71.88M | -100.28M | -91.40M | -92.84M | -54.86M | -15.08M | -6.05M | -3.03M |
| Operating Income Ratio | -85.48% | -3,458.05% | -44.50% | -265.33% | -208.31% | -354.77% | -284.72% | -426.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.74M | -3.67M | -1.09M | -997.00K | 1.60M | 1.34M | 2.02M | 1.26M | 76.00K | -1.63M | -50.00K | -93.00K |
| Income Before Tax | -113.72M | -250.16M | -65.58M | -89.13M | -70.28M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Income Before Tax Ratio | -90.02% | -3,509.50% | -45.25% | -268.33% | -203.68% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.67M | -4.08M | -2.67M | -6.04M | 1.34M | -1.59M | 2.23M | -804.00K | 1.63M | 42.00K | 0.00 |
| Net Income | -113.72M | -253.82M | -61.50M | -86.45M | -64.24M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Net Income Ratio | -90.02% | -3,560.94% | -42.43% | -260.29% | -186.19% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| EPS Diluted | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| Weighted Avg Shares Out | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
| Weighted Avg Shares Out (Dil) | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Call Transcript
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
Source: https://incomestatements.info
Category: Stock Reports